Cubillos-Ruiz Juan R, Sempere Lorenzo F, Conejo-Garcia Jose R
Department of Medicine; Weill Cornell Medical College; New York, NY USA ; The Ragon Institute of MGH; MIT and Harvard; Charlestown, MA USA.
Oncoimmunology. 2012 Sep 1;1(6):968-970. doi: 10.4161/onci.20020.
Current ovarian cancer treatments based on surgery/chemotherapy show limited efficacy. Targeting immunosuppression is a requirement for the effectiveness of novel promising anti-tumor immunotherapies. Our latest work in preclinical models shows that nanoparticle-mediated delivery of immunostimulatory microRNAs specifically to tumor-associated leukocytes is sufficient to re-program immunological control of metastatic ovarian cancers.
目前基于手术/化疗的卵巢癌治疗方法疗效有限。针对免疫抑制是新型有前景的抗肿瘤免疫疗法取得疗效的必要条件。我们在临床前模型中的最新研究表明,纳米颗粒介导的免疫刺激微RNA特异性递送至肿瘤相关白细胞足以重新编程转移性卵巢癌的免疫控制。